Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Filters applied. Clear all
Clinical Trial
. 2005 Jul 25;165(14):1618-23.
doi: 10.1001/archinte.165.14.1618.

A Randomized Controlled Trial of Vitamin D3 Supplementation in African American Women

Affiliations
Free PMC article
Clinical Trial

A Randomized Controlled Trial of Vitamin D3 Supplementation in African American Women

John F Aloia et al. Arch Intern Med. .
Free PMC article

Abstract

Background: We conducted a randomized, placebo-controlled, double-blind trial to test the hypothesis that vitamin D(3) supplementation would prevent bone loss in calcium-replete, African American postmenopausal women.

Methods: Two hundred eight healthy black postmenopausal women, 50 to 75 years of age, were assigned to receive either placebo or 20 microg/d (800 IU) of vitamin D(3). Calcium supplements were provided to ensure a total calcium intake of 1200 to 1500 mg/d. After 2 years, the vitamin D(3) dose was increased to 50 microg/d (2000 IU) in the active group, and the study continued for an additional year. Bone mineral density (BMD) was measured every 6 months. Markers of bone turnover, vitamin D metabolites, and parathyroid hormone (PTH) levels were measured in serum.

Results: There were no significant differences in BMD between the active and control groups throughout the study. There was also no relationship between serum 25-hydroxyvitamin D levels attained and rates of bone loss. There was an increase in BMD of the total body, hip, and radius at 1 year in both groups. Over the 3 years, BMD declined at these sites by 0.26% to 0.55% per year. The BMD of the lumbar spine increased slightly in the placebo and active groups. There were no persistent changes in serum PTH levels or the markers of bone turnover, although there was a transient decline in PTH in both groups at 3 months. No significant adverse events were attributed to vitamin D supplementation.

Conclusions: There was no observed effect of vitamin D(3) supplementation on bone loss or bone turnover markers in calcium-replete, postmenopausal African American women. Further studies are needed to determine if these findings are applicable to women of other ethnic groups.

Figures

Figure 1
Figure 1
Flowchart of subject progress through trial. HT indicates hormone therapy; AEs, adverse events.
Figure 2
Figure 2
Distribution of baseline 25-hydroxyvitamin D (25-OHD) among African American postmenopausal women (n = 208). To convert 25-OHD to nanomoles per liter, multiply by 2.496.
Figure 3
Figure 3
Box and whisker plots of the percent change from baseline for 4 body sites. There were no significant differences between groups. BMD indicates bone mineral density.

Similar articles

See all similar articles

Cited by 57 articles

See all "Cited by" articles

Publication types

Feedback